On June 12, 2025, the "Interdisciplinary Exchange Conference on the Application of Biologics in the Treatment of Psoriasis and Ankylosing Spondylitis," hosted by the Chengdu High-Tech Medical Association, will be held online. This conference focuses on the field of skin immune diseases, aiming to promote in-depth development in this area and enhance the diagnostic and therapeutic standards for related diseases.The treatment of skin immune diseases has always been a key research area in the medical field.

 In the past, treatments for such diseases often relied on偶然 discovered drugs or therapies, with unsatisfactory efficacy and long-term treatment risks of toxicity. With the advent of biologics, a new dawn has emerged in the treatment of skin immune diseases. Increasingly, patients are achieving ideal therapeutic outcomes with biologics, achieving complete or near-complete clearance of skin lesions and itching. However, numerous questions remain to be addressed in various aspects, including the pharmacological mechanisms of biologics, their rational and safe use, long-term patient management, and early intervention.Skin immune diseases such as psoriasis and urticaria significantly impact patients' quality of life, imposing a heavy physical and mental burden on them.

 This conference, centered on "The Application of Biologics in the Treatment of Psoriasis and Ankylosing Spondylitis," will adopt an interdisciplinary exchange model to facilitate discussions among experts from different specialties. The goal is to provide new insights into the precise diagnosis and treatment of skin immune diseases. The conference will conduct in-depth discussions on the rational and safe use of biologics in the treatment of psoriasis and ankylosing spondylitis, striving to provide scientific solutions for comprehensive disease management and alleviate patients' disease burden.It is believed that this exchange conference will gather wisdom from all sides, reach new consensus in the application of biologics and precise disease diagnosis and treatment, inject new vitality into the development of the field of skin immune diseases, and assist more patients in regaining their health.